Descripción del proyecto
Tratamiento de enfermedades de los sistemas ocular, nervioso, cardiovascular y el cáncer centrado en la vía de señalización de los cisteinil leucotrienos
Los cisteinil leucotrienos (CysLT, por sus siglas en inglés) son mediadores lipídicos conocidos de la inflamación. Los receptores de CysLT se encuentran en los pulmones, el tracto colorrectal, el corazón, el encéfalo y los ojos, y se utilizan sus antagonistas para el tratamiento de la inflamación. El proyecto CRYSTAL3, financiado con fondos europeos, creará un equipo multidisciplinar de cinco socios académicos y cinco industriales centrado en la investigación innovadora de la señalización de los CysLT en enfermedades humanas relacionadas con los sistemas ocular, nervioso y cardiovascular, y el cáncer. Entre los objetivos generales figuran la comprensión de nuevos mecanismos patológicos en los que intervenga la señalización de los CysLT, descubrir su potencial terapéutico y desarrollar productos comerciales.
Objetivo
Cysteinyl leukotrienes (CysLTs) are potent lipid mediators of inflammation. CysLT1 and 2 receptors are widely expressed e.g. lungs, colorectum, heart, brain & eye; and CysLT1 antagonists are prescribed to treat airway inflammation. Excitingly, CysLT signalling was recently discovered to regulate the biology of vascular, neuronal and cancer cells underpinning its untapped therapeutic potential in other diseases. CRYSTAL3 interconnects unique and diverse researchers to create a multidisciplinary team sharing expertise and research capacities. The contribution of CysLT signalling to disease is divulged; its therapeutic potential unlocked and new services & products commercialised. This is delivered by staff exchanges to jointly research Ocular & Central Nervous System (CNS), Cardiovascular system (CV) and Cancer diseases.
The R&I goal of CRYSTAL3 is to reduce human disease burden by enhancing EU capability and knowledge-sharing in research and commercialisation. This is achieved through advanced international co-operation between 5 academic and 5 non-academic partners, in 7 countries. The focus is on innovative research into the CysLT signalling pathway in human diseases related to the Ocular-CNS, & CV systems and Cancer (OCCC).
The 3 overall objectives of CRYSTAL3 are:
A) Combine resources to discover novel pathological mechanisms linking cysteinyl leukotriene signalling to ocular, central nervous system, cardiovascular disease and cancer (OCCC).
B) Unite partner capacities to uncover the therapeutic potential of cysteinyl leukotriene signalling in ocular, central nervous system, cardiovascular disease and cancer (OCCC).
C) Commercialise products and services co-developed within CRYSTAL3
The CRYSTAL3 consortium tackles these challenges by promoting cross-sector, inter-European R&I staff exchanges among participants with expertise in OCCC disease, computational drug discovery, genetic engineering, pre-clinical disease models, marketing and commercialisation.
Ámbito científico
- natural sciencesbiological sciencesneurobiology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesmedical biotechnologygenetic engineering
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesclinical medicineoncology
Palabras clave
Programa(s)
Régimen de financiación
MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)Coordinador
4 Dublin
Irlanda